CTOs on the Move

MedClean Technologies

www.medcleantechnologies.com

 
MedClean Technologies is a Bethel, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

American Addiction Centers

Why American Addiction Centers? We take a big picture approach to addiction recovery treatment – addressing the individual`s whole lifestyle in relation to substance use, alcohol and binge eating addiction and partnering with the family throughout the treatment process whenever possible. With our research-based programs, our inpatient treatment centers don`t just focus on the problem; we strengthen the individual and focus on the future. Whether it`s the initial clinical assessments, medically supervised detox, residential rehabilitation or aftercare, our team is present for and committed to each step of the recovery process for every individual. American Addiction Centers is an equal opportunity and drug free employer. All decisions regarding recruiting and hiring will be made without unlawful discrimination on the basis of race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, or age.

iTech Medical

iTech Medical is a Huntington Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Best Fitness

Best Fitness is a Chelmsford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dietz Hwkins Internal Medicine

Dietz Hwkins Internal Medicine is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alector

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.